← All trials
NCT00182312
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 1, 1999
- Primary completion
- Mar 1, 2007
- Completion date
- Jul 1, 2016
- First posted
- —
- Last posted
- —
- Enrollment
- 2000
- Arms / groups
- 1 / —
- Source
- AACT · pre-existing
Sponsors
- McMaster UniversityLead sponsor
- McMaster UniversityStudy director
- McMaster UniversityStudy chair
- Children & Women's Health Centre of BC, Vancouver, CanadaStudy director
- James Cook University Hospital, Middlesbrough, UKStudy director
- McGill UniversityStudy director
- University of TorontoStudy director
- University of British ColumbiaStudy director
- University of CalgaryStudy director
- University of ManitobaStudy director
- University of MelbourneStudy director
- Canadian Institutes of Health Research (CIHR)Collaborator
- National Health and Medical Research Council, AustraliaCollaborator
- McMaster UniversityReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.